• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

红细胞计数和红细胞沉降率在真性红细胞增多症诊断中的价值。

The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera.

机构信息

Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Department of Clinical Sciences, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.

出版信息

Eur J Haematol. 2020 Jan;104(1):46-54. doi: 10.1111/ejh.13334. Epub 2019 Nov 22.

DOI:10.1111/ejh.13334
PMID:31584701
Abstract

BACKGROUND

Iron deficiency in polycythaemia vera (PV) may impact the validity of the haematocrit (HCT), since HCT is red blood cell count (RBC) × mean corpuscular volume (MCV).

OBJECTIVES

To investigate (a) the effect of microcytosis on HCT, (b) the erythrocyte sedimentation rate (ESR) as a possible additional diagnostic marker for PV.

MATERIAL AND METHODS

This study included 182 subjects: 39 with PV, 27 with essential thrombocythemia (ET) and 116 suspected of myeloproliferative neoplasm (MPN) with a secondary cause for either thrombocytosis or erythrocytosis.

RESULTS

Patients with PV had significantly lower ratio of MCV and serum ferritin compared to MPN suspects. A good correlation of RBC versus HCT was found for PV and MPN subjects when individuals with microcytosis were excluded (R  = .87 in PV and R  = .82 in MPN suspects). We found a specificity of 98% and a sensitivity of 37% for ESR <2 mm in the diagnosis of PV.

CONCLUSION

The RBC may more precisely reflect the total red cell mass and accordingly the hypercoagulable state of the PV patient, which is integrated in the ESR. A combination of RBC and ESR is proposed as a novel tool to substitute the Hb concentration and the HCT in the diagnosis of PV.

摘要

背景

真性红细胞增多症(PV)中的铁缺乏可能会影响红细胞压积(HCT)的准确性,因为 HCT 是红细胞计数(RBC)×平均红细胞体积(MCV)。

目的

研究(a)小红细胞症对 HCT 的影响,(b)红细胞沉降率(ESR)作为 PV 的另一种可能的诊断标志物。

材料和方法

本研究纳入了 182 名受试者:39 名 PV 患者、27 名原发性血小板增多症(ET)患者和 116 名疑似骨髓增殖性肿瘤(MPN)患者,这些患者的血小板增多或红细胞增多有继发原因。

结果

与 MPN 疑似患者相比,PV 患者的 MCV 和血清铁蛋白比值明显更低。当排除小红细胞症患者后,PV 和 MPN 患者的 RBC 与 HCT 之间存在良好的相关性(PV 中 R  = .87,MPN 疑似患者中 R  = .82)。我们发现 ESR <2 毫米在诊断 PV 中的特异性为 98%,敏感性为 37%。

结论

RBC 可能更准确地反映总红细胞质量,从而反映 PV 患者的高凝状态,这与 ESR 相关。建议将 RBC 和 ESR 联合作为替代 Hb 浓度和 HCT 的新工具用于诊断 PV。

相似文献

1
The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera.红细胞计数和红细胞沉降率在真性红细胞增多症诊断中的价值。
Eur J Haematol. 2020 Jan;104(1):46-54. doi: 10.1111/ejh.13334. Epub 2019 Nov 22.
2
Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency.伴有小细胞性贫血的非 CML 经典骨髓增殖性疾病的分类不明:这些发现提示铁缺乏症掩盖了真性红细胞增多症的诊断。
Turk J Med Sci. 2019 Oct 24;49(5):1560-1563. doi: 10.3906/sag-1907-67.
3
The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.世界卫生组织真性红细胞增多症诊断标准-红细胞质量与血红蛋白/红细胞压积水平和形态的关系。
Ann Hematol. 2018 Sep;97(9):1581-1590. doi: 10.1007/s00277-018-3344-3. Epub 2018 May 1.
4
Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythaemia.真性红细胞增多症和相对性红细胞增多症中的红细胞总量、脾脏大小及血浆促红细胞生成素
Acta Haematol. 2002;108(1):1-7. doi: 10.1159/000063064.
5
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
6
An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia.静脉血红蛋白浓度升高不能用作绝对红细胞增多症的替代标志物:真性红细胞增多症和相对性红细胞增多症患者的研究。
Br J Haematol. 2005 Jun;129(5):701-5. doi: 10.1111/j.1365-2141.2005.05517.x.
7
Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke.真性红细胞增多症患者的红细胞形态动力学与中风。
Int J Mol Sci. 2022 Feb 17;23(4):2247. doi: 10.3390/ijms23042247.
8
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.真性红细胞增多症和原发性血小板增多症:2013 年诊断、危险分层和治疗更新。
Am J Hematol. 2013 Jun;88(6):507-16. doi: 10.1002/ajh.23417.
9
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.血清促红细胞生成素水平及JAK2 V617F等位基因负荷在真性红细胞增多症诊断中的作用。
Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.
10
Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms.根据2016年世界卫生组织(WHO)髓系肿瘤新分类,全血细胞计数正常个体的红细胞增多症发生率
Int J Lab Hematol. 2017 Oct;39(5):528-531. doi: 10.1111/ijlh.12686. Epub 2017 May 12.

引用本文的文献

1
The Role of Erythrocyte Sedimentation Rate (ESR) in Myeloproliferative and Lymphoproliferative Diseases: Comparison between DIESSE CUBE 30 TOUCH and Alifax Test 1.红细胞沉降率(ESR)在骨髓增殖性疾病和淋巴细胞增殖性疾病中的作用:迪赛CUBE 30 TOUCH与阿利法克斯Test 1的比较
Diseases. 2023 Nov 15;11(4):169. doi: 10.3390/diseases11040169.
2
Relevant detection indicator of prethrombotic state in patients with primary hypertension.原发性高血压患者血栓前状态的相关检测指标
World J Clin Cases. 2023 Aug 26;11(24):5678-5691. doi: 10.12998/wjcc.v11.i24.5678.
3
Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study.
慢性骨髓增殖性肿瘤患者的髋膝关节骨关节炎:一项横断面研究
Life (Basel). 2023 Jun 14;13(6):1388. doi: 10.3390/life13061388.
4
Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?真性红细胞增多症与原发性血小板增多症鉴别诊断中红细胞计数和红细胞量恢复正常的时间?
Haematologica. 2019 Nov;104(11):2119-2125. doi: 10.3324/haematol.2019.229039.